(Reuters)—Europe’s drugs regulator said on Monday it was evaluating the use of Roche’s arthritis drug, tocilizumab, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment. Tocilizumab, sold by Roche as Actemra and RoActemra, has shown promise in clinical trials in treating COVID-19, and was approved by U.S. health regulators in…
International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19
One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
COVID-19 Vaccination in Patients with Rheumatic Disease
With a large percentage of the U.S. population unsure whether they will get vaccinated against COVID-19, rheumatology patients remain vulnerable. On May 13, the ACR hosted a virtual town hall highlighting ways rheumatology providers might effectively approach their patients who have not yet decided to get a COVID-19 vaccine. Get the Slow Yes At the…
CDC Advisers Consider Boosters for Immune-Compromised Americans
CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…
Generally Favorable Outcomes 6 Months After COVID-Linked Inflammatory Syndrome in Kids
NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…
U.S. to Announce New Warning on J&J Coronavirus Vaccine for Guillain-Barré Syndrome
(Reuters)—The U.S. Food & Drug Administration (FDA) is expected to announce a new warning on Johnson & Johnson’s (J&J’s) coronavirus vaccine related to a rare autoimmune disorder, The Washington Post reported on Monday, citing four people familiar with the matter.1 According to The Post, about 100 preliminary reports of Guillain-Barré syndrome have been detected in the…
Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…
Researchers Explore Response to COVID-19 Vaccines in the Elderly
A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.
Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations
Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.
COVID-19 Puts Latino Patients with Rheumatic Disease at Risk of a Disease Flare
In their new study, Fike et al. found Latino patients with rheumatic diseases have a higher rate of COVID-19 than the general Latino population. Obesity is a risk factor for COVID-19, and COVID-19 is a risk factor for rheumatic disease flare.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 27
- Next Page »